XCUR (Exicure) Moat Score: 3/10 (As of Jul. 06, 2026)


XCUR Exicure Inc XCUR
32 GF Score
Price $2.00
GF Value $0.54
Valuation Significantly Overvalued
! 2 Warning Signs
View Full Analysis

What is Exicure Moat Score?

Exicure XCUR +4.45% 32 Moat Score is 3 as of Jul. 06, 2026. GuruFocus rates XCUR with a GF Score™ of 32/100 and a GF Value™ of $0.54 (Significantly Overvalued). The stock has 2 warning signs investors should review. Among 1,395 Biotechnology companies, Exicure ranks better than 75.56% on this metric.

Exicure has the Moat Score of 3, which implies that the company might have No Moat - Very weak/transient advantages.

Exicure has No Moat: Exicure Inc has some intellectual property but lacks strong market leadership and customer loyalty. The company does not have significant cost advantages or regulatory barriers, and its innovation capabilities are not yet impactful enough to establish a durable moat.

Moat Score is a ranking system developed by GuruFocus to assess a company's ability to sustain a competitive advantage, rated on a scale from 0 to 10. It takes into account key factors such as market leadership, cost advantages, network effects, customer switching costs, and more.

The company's Moat Score is based on these criteria:

1. Market leadership and sustainable market share
2. Network effects and significant customer switching costs
3. Valuable intellectual property and patents
4. Strong brand strength and deep customer loyalty
5. Durable cost advantages (e.g., economies of scale, proprietary technology)
6. Significant regulatory barriers and exclusive licenses
7. Superior distribution network
8. Strong and sustainable pricing power
9. Consistent and impactful innovation and R&D capabilities

Based on the research, GuruFocus believes Exicure might have No Moat - Very weak/transient advantages.

Exicure  (NAS:XCUR) Moat Score Explanation

The Moat Score ranges from 0 to 10, with 10 as the highest. GuruFocus divided Moat Score into following 8 categories:

Moat Score Moat Level
10Wide Moat - Exceptionally dominant and durable wide moat
8 - 9Wide Moat - Clear and robust wide moat
7Wide Moat - Entry-level wide moat, clearly possessing durable advantages
6Narrow Moat - Strong narrow moat, clearly distinguishable but not wide
5Narrow Moat - Solid narrow moat
4Narrow Moat - Discernible but modest moat
1 - 3No Moat - Very weak/transient advantages
0No Moat - No discernible moat

Exicure Moat Score Related Terms

XCUR vs TVRD, ANEB, HOWL: Moat Score Comparison

For the Biotechnology subindustry, Exicure's Moat Score, along with its competitors' market caps and Moat Score data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.

Exicure Moat Score vs Biotechnology Industry

For the Biotechnology industry and Healthcare sector, Exicure's Moat Score distribution charts can be found below:

* The bar in red indicates where Exicure's Moat Score falls into.


XCUR
32GF Score
Exicure Inc XCUR
Moat Score is just one metric. See GF Score™, valuation, warning signs, and more.
View Full Analysis
Frequently Asked Questions Learn more about Moat Score →
What does a Moat Score of 3 mean?
Exicure (XCUR) has a Moat Score of 3 as of Jul. 06, 2026. Moat Score is a ranking system developed by GuruFocus to assess a company's ability to sustain a competitive advantage, rated on a scale from 0 to 10. It takes into account key factors such as market leadership, cost advantages, network effects, customer switching costs, and more. According to the industry distribution chart, Exicure ranks #341 out of 1395 companies in the Biotechnology industry, placing it in the top 24.4%.
Is Exicure's Moat Score too high?
Exicure's current Moat Score is 3. The Biotechnology industry median Moat Score is 2.00. Exicure's value of 3 is 50% above this industry median. Based on the distribution chart, Exicure ranks #341 out of 1395 companies in the Biotechnology industry, which is in the top quartile — a strong position relative to peers. Overall, Exicure has a GF Score™ of 32/100 and is considered Significantly Overvalued, reflecting its overall financial health beyond just this single metric.
How does Exicure's Moat Score compare to TVRD and ANEB?
According to the Biotechnology industry distribution chart, Exicure ranks #341 out of 1395 companies for Moat Score. This places Exicure in the top 24% of its industry — outperforming the majority of peers. The industry median Moat Score is 2.00. Exicure's value of 3 is 50% above this benchmark. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good Moat Score for a Biotechnology company?
The median Moat Score among Biotechnology companies is 2.00, based on 1,395 companies in the industry. Companies in the top quartile (top 25%) have a Moat Score significantly above this median, while those in the bottom quartile fall well below. However, Moat Score should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Exicure's current Moat Score of 3 is 50% above the industry median. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high Moat Score mean?
A high Moat Score can signal that a stock is expensive relative to its fundamentals. Moat Score is a ranking system developed by GuruFocus to assess a company's ability to sustain a competitive advantage, rated on a scale from 0 to 10. It takes into account key factors such as market leadership, cost advantages, network effects, customer switching costs, and more. For the Biotechnology industry, the median Moat Score is 2.00 — values significantly above this may indicate overvaluation, while values below may suggest a bargain or underlying issues. Exicure's current Moat Score is 3. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Exicure stock overvalued right now?
Based on GuruFocus' analysis, Exicure (XCUR) is currently considered Significantly Overvalued. The stock's GF Value™ is $0.54, compared to a current price of $2.00 — trading 269.4% above its estimated fair value. The current Moat Score is 3 and 50% above the Biotechnology industry median of 2.00. Exicure's overall GF Score™ is 32/100 with 2 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is Moat Score calculated?
Moat Score is calculated from a company's financial statements. For Exicure (XCUR), the current Moat Score is 3 as of Jul. 06, 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.

Is Exicure (XCUR) Overvalued in 2026?

Based on GuruFocus' analysis, Exicure stock appears to be overvalued. The current stock price of $2.00 is trading 269.4% above its estimated GF Value™ of $0.54. GuruFocus considers Exicure to be Significantly Overvalued.

Key valuation signals for XCUR:

  • Moat Score: 3
  • GF Value™: $0.54 vs. price of $2.00 (269.4% above fair value)
  • GF Score™: 32/100 with 2 warning signs
  • Industry Position: 50% above the Biotechnology median (#341 of 1395)

No single metric tells the full story. See the XCUR stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.

Exicure Business Description

Other Exchanges 2H0:Germany
Address 400 Seaport Court, Suite 102, Redwood City, CA, USA, 94063
Exicure Inc is a clinical-stage biotechnology company focused on developing treatments for blood-related diseases, with an emphasis on small-molecule therapies that have the potential to benefit a broad range of patients. The company acquired GPCR Therapeutics USA and secured a license for GPC-100 (Burixafor), a clinical-stage small-molecule compound that inhibits the chemokine receptor CXCR4. GPC-100 has demonstrated the ability to effectively mobilize various cell types, including hematopoietic stem cells and lymphocytes, highlighting its broad therapeutic potential across multiple indications.
32GF Score

Get the complete analysis for XCUR

Moat Score is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.

$2.00
Price
$0.54
GF Value